Minoxidil

Anastassakis, Konstantinos

doi:10.1007/978-3-031-08057-9_1

Konstantinos Anastassakis²

716 Accesses

Abstract

In the 1970s, the American pharmaceutical company Upjohn & Pharmacia developed the antihypertensive drug Minoxidil and launched it under the brand name Loniten^®, in the form of 2.5 mg and 10 mg tablets. Minoxidil is a pyrimidine derivative (2,4 diamino-6-piperidinopyrimidine-3-oxide), has a molecular weight of 209.25, and its action is focused on vascular adenosine triphosphate-sensitive potassium channels (K^ATP). Intravenous and oral Minoxidil will potently reduce both systolic and diastolic pressure, as well as the peripheral resistance of arteries, but not veins [1]. Minoxidil is very potent, and its antihypertensive use seemed, in the beginning, particularly promising for the management of severe, refractory hypertension [2].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Chapter: USD 29.95; Price excludes VAT (USA)

eBook: USD 99.00; Price excludes VAT (USA)

Softcover Book: USD 129.99; Price excludes VAT (USA)

Hardcover Book: USD 199.99; Price excludes VAT (USA)

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

Chidsey CA 3rd, Gottlieb TB. The pharmacologic basis of antihypertensive therapy: The role of vasodilator drugs. Prog Cardiovasc Dis. 1974;17(2):99–113.
PubMed Google Scholar
Mehta PK, Mamdani B, Shansky RM, Mahurkar SD, Dunea G. Severe hypertension. Treatment with minoxidil JAMA. 1975;233(3):249–52.
CAS PubMed Google Scholar
Burton JL, Marshall A. Hypertrichosis due to minoxidil. Br J Dermatol. 1979;101(5):593–5.
CAS PubMed Google Scholar
Jacomb RG, Brunnberg FJ. The use of minoxidil in the treatment of severe essential hypertension: a report on 100 patients. Clin Sci Mol Med Suppl. 1976;3:579s–81s.
CAS PubMed Google Scholar
Devine BL, Fife R, Trust PM. Minoxidil for severe hypertension after failure of other hypotensive drugs. Br Med J. 1977;2(6088):667–9.
CAS PubMed PubMed Central Google Scholar
Dargie HJ, Dollery CT, Daniel J. Minoxidil in resistant hypertension. Lancet. 1977;2(8037):515–8.
CAS PubMed Google Scholar
Pennisi AJ, Takahashi M, Bernstein BH, Singsen BH, Uittenbogaart C, Ettenger RB, Malekzadeh MH, Hanson V, Fine RN. Minoxidil therapy in children with severe hypertension. J Pediatr. 1977;90(5):813–9.
CAS PubMed Google Scholar
Zappacosta AR. Reversal of baldness in patient receiving minoxidil for hypertension. N Engl J Med. 1980;303(25):1480–1.
CAS PubMed Google Scholar
Weiss VC, West DP, Mueller CE. Topical minoxidil in alopecia areata. J Am Acad Dermatol. 1981;5(2):224–6.
CAS PubMed Google Scholar
Unapproved use of minoxidil. FDA Drug Bull. 1985;15(4):38.
Google Scholar
Sasson M, Shupack JL, Stiller MJ. Status of medical treatment for androgenetic alopecia. Int J Dermatol. 1993;32(10):701–6.
CAS PubMed Google Scholar
Rogers NE, Avram MR. Medical treatments for male and female pattern hair loss. J Am Acad Dermatol. 2008;59(4):547–66.
PubMed Google Scholar
Ashcroft FM. From molecule to malady. Nature. 2006;440(7083):440–7.
CAS PubMed Google Scholar
Nichols CG. KATP channels as molecular sensors of cellular metabolism. Nature. 2006;440(7083):470–6.
CAS PubMed Google Scholar
Ashcroft FM, Gribble FM. New windows on the mechanism of action of K(ATP) channel openers. Trends Pharmacol Sci. 2000;21(11):439–45.
CAS PubMed Google Scholar
Messenger AG, Rundegren J. Minoxidil: mechanisms of action on hair growth. Br J Dermatol. 2004;150(2):186–94.
CAS PubMed Google Scholar
Davies GC, Thornton MJ, Jenner TJ, Chen YJ, Hansen JB, Carr RD, Randall VA. Novel and established potassium channel openers stimulate hair growth in vitro: implications for their modes of action in hair follicles. J Invest Dermatol. 2005;124(4):686–94.
CAS PubMed Google Scholar
Shorter K, Farjo NP, Picksley SM, Randall VA. Human hair follicles contain two forms of ATP-sensitive potassium channels, only one of which is sensitive to minoxidil. FASEB J. 2008;22(6):1725–36.
CAS PubMed Google Scholar
Headington JT. Hair follicle biology and topical minoxidil: possible mechanisms of action. Dermatologica. 1987;175(Suppl 2):19–22.
PubMed Google Scholar
Wester RC, Maibach HI, Guy RH, Novak E. Minoxidil stimulates cutaneous blood flow in human balding scalps: pharmacodynamics measured by laser Doppler velocimetry and photopulse plethysmography. J Invest Dermatol. 1984;82(5):515–7.
CAS PubMed Google Scholar
de Boer EM, Bezemer PD, Bruynzeel DP, Nieboer C. Does topical minoxidil increase skin blood flow? A laser Doppler flowmetry study. Acta Derm Venereol. 1988;68(3):271–4.
PubMed Google Scholar
Olsen EA, DeLong E. Transdermal viprostol in the treatment of male pattern baldness. J Am Acad Dermatol. 1990;23(3 Pt 1):470–2.
CAS PubMed Google Scholar
Bunker CB, Dowd PM. Alterations in scalp blood flow after the epicutaneous application of 3% minoxidil and 0.1% hexyl nicotinate in alopecia. Br J Dermatol. 1987;117(5):668–9.
CAS PubMed Google Scholar
Michelet JF, Commo S, Billoni N, Mahé YF, Bernard BA. Activation of cytoprotective prostaglandin synthase-1 by minoxidil as a possible explanation for its hair growth-stimulating effect. J Invest Dermatol. 1997;108(2):205–9.
CAS PubMed Google Scholar
Garza LA, Liu Y, et al. Prostaglandin d2 inhibits hair growth and is elevated in bald scalp of men with androgenetic alopecia. Sci Transl Med. 2012;4(126):126ra34.
PubMed PubMed Central Google Scholar
Colombe L, Vindrios A, Michelet JF, Bernard BA. Prostaglandin metabolism in human hair follicle. Exp Dermatol. 2007;16(9):762–9.
CAS PubMed Google Scholar
Sato T, Tadokoro T, Sonoda T, Asada Y, Itami S, Takayasu S. Minoxidil increases 17 beta-hydroxysteroid dehydrogenase and 5 alpha-reductase activity of cultured human dermal papilla cells from balding scalp. J Dermatol Sci. 1999;19(2):123–5.
CAS PubMed Google Scholar
Pinnell SR, Murad S. Effects of minoxidil on human skin fibroblasts in culture. Clin Dermatol. 1988;6(4):152–8.
CAS PubMed Google Scholar
Hautala T, Heikkinen J, Kivirikko KI, Myllyla R. Minoxidil specifically decreases the expression of lysine hydroxylase in cultured human skin fibroblasts. Biochem J. 1992;283(Pt 1):51–4.
CAS PubMed PubMed Central Google Scholar
Buhl AE, Waldon DJ, Baker CA, Johnson JA. Minoxidil sulfate is the active metabolite that stimulates hair follicles. J Invest Dermatol. 1990;95(5):553–7.
CAS PubMed Google Scholar
Anderson RJ, Kudlacek PE, Clemens DL. Sulfation of minoxidil by multiple human cytosolic sulfotransferases. Chem Biol Interact. 1998;109(1–3):53.
CAS PubMed Google Scholar
Johnson GA, Barsuhn KJ, McCall JM. Sulfation of minoxidil by liver sulfotransferase. Biochem Pharmacol. 1982;31(18):2949–54.
CAS PubMed Google Scholar
Meisheri KD, Johnson GA, Puddington L. Enzymatic and non-enzymatic sulfation mechanisms in the biological actions of minoxidil. Biochem Pharmacol. 1993;45(2):271–9.
CAS PubMed Google Scholar
Dooley TP. Molecular biology of the human cytosolic sulfotransferase gene superfamily implicated in the bioactivation of minoxidil and cholesterol in skin. Exp Dermatol. 1999;8(4):328–9.
CAS PubMed Google Scholar
Ohttsuyama M. Minoxidil sulfate effect of internal calcium of cell in the epidermis and epidermal appendages. In: Van Neste VRD. Hair Research for the next Millenium. Amsterdam: Elsevier Science; 1996. p. 481.
Google Scholar
Buhl AE. Minoxidil’s action in hair follicles. J Invest Dermatol. 1991;96(5):73S–4S.
CAS PubMed Google Scholar
Buhl AE, Baker CA, Dietz AJ. Minoxidil sulfotransferase activity influences the efficacy of Rogaine topical solution (TS): enzyme studies using scalp and platelets. J Invest Dermatol. 1994;102(4):534.
Google Scholar
Whiting DA. Diagnostic and predictive value of horizontal sections of scalp biopsy specimens in male pattern androgenetic alopecia. J Am Acad Dermatol. 1993;28(5 Pt 1):755–63.
CAS PubMed Google Scholar
Boyera N, Galey I, Bernard BA. Biphasic effects of minoxidil on the proliferation and differentiation of normal human keratinocytes. Skin Pharmacol. 1997;10(4):206–20.
CAS PubMed Google Scholar
Malhi H, Irani AN, Rajvanshi P, et al. KATP channels regulate mitogenically induced proliferation in primary rat hepatocytes and human liver cell lines. Implications for liver growth control and potential therapeutic targeting. J Biol Chem. 2000;275(34):26050–7.
CAS PubMed Google Scholar
Xu D, Wang L, Dai W, Lu L. A requirement for K+-channel activity in growth factor-mediated extracellular signal-regulated kinase activation in human myeloblastic leukemia ML-1 cells. Blood. 1999;94(1):139–45.
CAS PubMed Google Scholar
Uno H, Kurata S. Chemical agents and peptides affect hair growth. J Invest Dermatol. 1993;101(1 Suppl):143S–7S.
CAS PubMed Google Scholar
Lachgar S, Charveron M, Gall Y, Bonafe JL. Minoxidil upregulates the expression of vascular endothelial growth factor in human hair dermal papilla cells. Br J Dermatol. 1998;138(3):407–11.
CAS PubMed Google Scholar
Li M, Marubayashi A, Nakaya Y, Fukui K, Arase S. Minoxidil-induced hair growth is mediated by adenosine in cultured dermal papilla cells: possible involvement of sulfonylurea receptor 2B as a target of minoxidil. J Invest Dermatol. 2001;117(6):1594–600.
CAS PubMed Google Scholar
Yamazaki M, Tsuboi R, Lee YR, et al. Hair cycle-dependent expression of hepatocyte growth factor (HGF) activator, other proteinases, and proteinase inhibitors correlates with the expression of HGF in rat hair follicles. J Investig Dermatol Symp Proc. 1999;4(3):312–5.
CAS PubMed Google Scholar
Murad S, Tennant MC, Pinnell SR. Structure-activity relationship of minoxidil analogs as inhibitors of lysyl hydroxylase in cultured fibroblasts. Arch Biochem Biophys. 1992;292(1):234–8.
CAS PubMed Google Scholar
Kvedar JC, Baden HP, Levine L. Selective inhibition by minoxidil of prostacyclin production by cells in culture. Biochem Pharmacol. 1988;37(5):867–74.
CAS PubMed Google Scholar
O’Keefe E, Payne RE Jr. Minoxidil: inhibition of proliferation of keratinocytes in vitro. J Invest Dermatol. 1991;97(3):534–6.
PubMed Google Scholar
Orfanos CE, Happle R. Hair and hair Diseases. New York: Springer; 1990. p. 94.
Google Scholar
Han JH, Kwon OS, Chung JH, Cho KH, Eun HC, Kim KH. Effect of minoxidil on proliferation and apoptosis in dermal papilla cells of human hair follicle. J Dermatol Sci. 2004;34(2):91–8.
CAS PubMed Google Scholar
Kwack MH, Kang BM, Kim MK, Kim JC, Sung YK. Minoxidil activates β-catenin pathway in human dermal papilla cells: a possible explanation for its anagen prolongation effect. J Dermatol Sci. 2011;62(3):154–9.
CAS PubMed Google Scholar
Nuck BA, Fogelson SL, Lucky AW. Topical Minoxidil does not act as an antiandrogen in the flank organ of the golden Syrian hamster. Arch Dermatol. 1987;123(1):59–61.
CAS PubMed Google Scholar
Hsu CL, Liu JS, Lin AC, Yang CH, Chung WH, Wu WG. Minoxidil may suppress androgen receptor-related functions. Oncotarget. 2014;5(8):2187–97.
PubMed PubMed Central Google Scholar
Stamatas GN, Wu J, Pappas A, Mirmirani P, McCormick TS, Cooper KD, Consolo M, Schastnaya J, Ozerov IV, Aliper A, Zhavoronkov A. An analysis of gene expression data involving examination of signaling pathways activation reveals new insights into the mechanism of action of minoxidil topical foam in men with androgenetic alopecia. Cell Cycle. 2017;16(17):1578–84.
CAS PubMed PubMed Central Google Scholar
Mirmirani P, Consolo M, Oyetakin-White P, Baron E, Leahy P, Karnik P. Similar response patterns to topical minoxidil foam 5% in frontal and vertex scalp of men with androgenetic alopecia: a microarray analysis. Br J Dermatol. 2015;172(6):1555–61.
CAS PubMed Google Scholar
Abell E. Histologic response to topically applied minoxidil in male-pattern alopecia. Clin Dermatol. 1988;6(4):191–4.
CAS PubMed Google Scholar
Arck PC, Handjiski B, Peters EM, Hagen E, Klapp BF, Paus R. Topical minoxidil counteracts stress-induced hair growth inhibition in mice. Exp Dermatol. 2003;12(5):580–9.
CAS PubMed Google Scholar
Kwon OS, Oh JK, Kim MH, Park SH, Pyo HK, Kim KH, Cho KH, Eun HC. Human hair growth ex vivo is correlated with in vivo hair growth: selective categorization of hair follicles for more reliable hair follicle organ culture. Arch Dermatol Res. 2006;297(8):367–71.
PubMed Google Scholar
Shapiro J, Price VH. Hair regrowth. Therapeutic agents Dermatol Clin. 1998;16(2):341–56.
CAS PubMed Google Scholar
Uno H, Cappas A, Schlagel C. Cyclic dynamics of hair follicles and the effect of minoxidil on the bald scalps of stumptailed macaques. Am J Dermatopathol. 1985;7(3):283–97.
CAS PubMed Google Scholar
Takashima I, Adachi K, Montagna W. Studies of common baldness in the stumptailed macaque. IV. In vitro metabolism of testosterone in the hair follicles. J Invest Dermatol. 1970;55(5):329–34.
CAS PubMed Google Scholar
Uno H, Cappas A, Brigham P. Action of topical minoxidil in the bald stump-tailed macaque. J Am Acad Dermatol. 1987;16(3 Pt 2):657–68.
CAS PubMed Google Scholar
Regaine 5% Solution Minoxidil for topical use Monograph, May 2004.
Google Scholar
Olsen EA, DeLong ER, Weiner MS. Dose-response study of topical minoxidil in male pattern baldness. J Am Acad Dermatol. 1986;15(1):30–7.
CAS PubMed Google Scholar
Olsen EA, Weiner MS. Topical Minoxidil in male pattern baldness: effects of discontinuation of treatment. J Am Acad Dermatol. 1987;17(1):97–101.
CAS PubMed Google Scholar
Rietschel RL, Duncan SH. Safety and efficacy of topical minoxidil in the management of androgenetic alopecia. J Am Acad Dermatol. 1987;16(3 Pt 2):677–85.
CAS PubMed Google Scholar
Rushton DH, Unger WP, Cotterill PC, Kingsley P, James KC. Quantitative assessment of 2% topical minoxidil in the treatment of male pattern baldness. Clin Exp Dermatol. 1989;14(1):40–6.
CAS PubMed Google Scholar
Price VH, Menefee E. Quantitative estimation of hair growth. I. Androgenetic alopecia in women: effect of Minoxidil. J Invest Dermatol. 1990;95(6):683–7.
CAS PubMed Google Scholar
Olsen E. Treatment of androgenetic alopecia with topical Minoxidil solution. Res Staff Phys. 1989;35(1):53–69.
Google Scholar
Fiedler-Weiss VC. Topical minoxidil solution (1% and 5%) in the treatment of alopecia areata. J Am Acad Dermatol. 1987;16(3 Pt 2):745–8.
CAS PubMed Google Scholar
Price VH, Menefee E, Strauss PC. Changes in hair weight and hair count in men with androgenetic alopecia, after application of 5% and 2% topical Minoxidil, placebo, or no treatment. J Am Acad Dermatol. 1999;41(5 Pt 1):717–21.
CAS PubMed Google Scholar
Οlsen EA, Dunlap FE, Funicella T. A randomized clinical trial of 5% topical Minoxidil versus 2% topical Minoxidil and placebo in the treatment of androgenic alopecia in men. J Am Acad Dermatol. 2002;47(3):377–85.
Google Scholar
DeVillez RL, Jacobs JP, Szpunar CA, Warner ML. Androgenetic alopecia in the female. Treatment with 2% topical minoxidil solution. Arch Dermatol. 1994;130(3):303–7.
CAS PubMed Google Scholar
Jacobs JP, Szpunar CA, Warner ML. Use of topical minoxidil therapy for androgenetic alopecia in women. Int J Dermatol. 1993;32(10):758–62.
CAS PubMed Google Scholar
Trancik RJ, Strauss PC, Albert DG, Means LK. Comparison of 5% topical Minoxidil, ROGAINE Topical Solution 2% and placebo in the treatment of female androgenetic alopecia (Protocol M/7415/0009). Upjohn Technical Report 9153–94-006. Unpublished; October 14, 1994.
Google Scholar
Trancik RJ, Strauss PC, Albert DG, Means LK, Sheu WP. Efficacy comparison of 5% topical Minoxidil, ROGAINE Topical Solution 2% and placebo in the treatment of female androgenetic alopecia (Protocol M/7415/0286). Upjohn Technical Report 9153–94-003. Unpublished; October 14, 1994.
Google Scholar
Whiting DA, Jacobson C. Treatment of female androgenetic alopecia with Minoxidil 2%. Int J Dermatol. 1992;31(11):800–4.
CAS PubMed Google Scholar
Lucky AW, Piacquadio DJ, Ditre CM, Dunlap F, Kantor I, Pandya AG, Savin RC, Tharp MD. A randomized, placebo-controlled trial of 5% and 2% topical Minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol. 2004;50(4):541–53.
PubMed Google Scholar
Rundegren J. Pattern alopecia: what clinical features determine the response to topical minoxidil treatment? 4th Intercontinental Hair Research Societies Meeting, Berlin, June 17-19. J Dtsch Dermatol Ges. 2004;2:500. (abstract B2.4)
Google Scholar
DeVillez RL. Topical minoxidil for androgenetic alopecia: optimizing the chance for success by appropriate patient selection. Dermatologica. 1987;175(Suppl 2):50–3.
PubMed Google Scholar
Vogt A, Hadam S, Heiderhoff M, Audring H, Lademann J, Sterry W, Blume-Peytavi U. Morphometry of human terminal and vellus hair follicles. Exp Dermatol. 2007;16(11):946–50.
PubMed Google Scholar
Miranda BH, Tobin DJ, Sharpe DT, Randall VA. Intermediate hair follicles: a new more clinically relevant model for hair growth investigations. Br J Dermatol. 2010;163(2):287–95.
CAS PubMed Google Scholar
Savin RC, Atton AV. Minoxidil. Update on its clinical role. Dermatol Clin. 1993;11(1):55–64.
CAS PubMed Google Scholar
Sinclair R. Male pattern androgenetic alopecia. BMJ. 1998;317(7162):865–9.
CAS PubMed PubMed Central Google Scholar
Olsen EA, Whiting D, Bergfeld W, et al. A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2007;57(5):767–74.
PubMed Google Scholar
Kanti V, Hillmann K, Kottner J, Stroux A, Canfield D, Blume-Peytavi U. Effect of minoxidil topical foam on frontotemporal and vertex androgenetic alopecia in men: a 104-week open-label clinical trial. J Eur Acad Dermatol Venereol. 2016 Jul;30(7):1183–9.
CAS PubMed Google Scholar
Kanti V, Messenger A, Dobos G, Reygagne P, Finner A, Blumeyer A, Trakatelli M, Tosti A, Del Marmol V, Piraccini BM, Nast A, Blume-Peytavi U. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men - short version. J Eur Acad Dermatol Venereol. 2018;32(1):11–22.
CAS PubMed Google Scholar
Gupta AK, Charrette A. Topical minoxidil: systematic review and meta-analysis of its efficacy in androgenetic alopecia. Skinmed. 2015;13(3):185–9.
PubMed Google Scholar
Adil A, Godwin M. The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis. J Am Acad Dermatol. 2017 Jul;77(1):136–41.
PubMed Google Scholar
Gupta AK, Mays RR, Dotzert MS, Versteeg SG, Shear NH, Piguet V. Efficacy of non-surgical treatments for androgenetic alopecia: a systematic review and network meta-analysis. J Eur Acad Dermatol Venereol. 2018;32(12):2112–25.
CAS PubMed Google Scholar
DeVillez RL. Topical Minoxidil therapy in hereditary androgenic alopecia. Arch Dermatol. 1985;121(2):197–202.
CAS Google Scholar
Price VH. Treatment of hair loss. New Engl J Med. 1999;341(13):964–73.
CAS PubMed Google Scholar
Olsen EA, Weiner MS, Amara IA, DeLong ER. Five-year follow-up of men with androgenetic alopecia treated with topical minoxidil. J Am Acad Dermatol. 1990;22(4):643–6.
CAS PubMed Google Scholar
Tosti A, Iorizzo M, Vincenzi C. Finasteride treatment may not prevent telogen effluvium after minoxidil withdrawal. Arch Dermatol. 2003;139(9):1221–2.
PubMed Google Scholar
Kidwai BJ, George M. Hair loss with minoxidil withdrawal. Lancet. 1992;340(8819):609–10.
CAS PubMed Google Scholar
Bardelli A, Rebora A. Telogen effluvium and minoxidil. J Am Acad Dermatol. 1989;21(3 Pt 1):572–3.
CAS PubMed Google Scholar
Bamford JT. A falling out following minoxidil: telogen effluvium. J Am Acad Dermatol. 1987;16(1 Pt 1):144–6.
CAS PubMed Google Scholar
Rossi A, Cantisani C, Melis L, Iorio A, Scali E, Calvieri S. Minoxidil use in dermatology, side effects and recent patents. Recent Patents Inflamm Allergy Drug Discov. 2012;6(2):130–6.
CAS Google Scholar
Eller MG, Szpunar JG, Della-Coletta AA. Absorption of Minoxidil after topical application: Effect of frequency and site of application. Clin Pharmacol Ther. 1989;45(4):396–402.
CAS PubMed Google Scholar
Shin HS, Won CH, Lee SH, Kwon OS, Kim KH, Eun HC. Efficacy of 5% minoxidil versus combined 5% minoxidil and 0.01% tretinoin for male pattern hair loss: a randomized, double-blind, comparative clinical trial. Am J Clin Dermatol. 2007;8(5):285–90.
PubMed Google Scholar
Ferry JJ, Forbes KK, LanderLugt JT, Szpunar GJ. Influence of tretinoin on the percutaneous absorption of Minoxidil from an aqueous topical solution. Clin Pharmacol Ther. 1990;47(4):439–46.
CAS PubMed Google Scholar
Kim JC, Lee MH, Rang MJ. Minoxidil-containing dosage forms: skin retention and after-rinsing hair-growth promotion. Drug Deliv. 2003;10(2):119–23.
CAS PubMed Google Scholar
Lademann J, Knorr F, Richter H, Blume-Peytavi U, Vogt A, Antoniou C, Sterry W, Patzelt A. Hair follicles—an efficient storage and penetration pathway for topically applied substances. Summary of recent results obtained at the Center of Experimental and Applied Cutaneous Physiology, Charité–Universitätsmedizin Berlin, Germany. Skin Pharmacol Physiol. 2008;21(3):150–5.
CAS PubMed Google Scholar
Otberg N, Richter H, Knuttel A, Schaefer H, Sterry W, Lademann J. Laser spectroscopic methods for the characterization of open and closed follicles. Laser Phys Lett. 2004;1(1):46–9.
Google Scholar
Ferry JJ, Shepard JH, Szpunar GJ. Relationship between contact time of applied dose and percutaneous absorption of minoxidil from a topical solution. J Pharm Sci. 1990;79(6):483–6.
CAS PubMed Google Scholar
Koperski JA, Orenberg EK, Wilkinson DI. Topical minoxidil therapy for androgenetic alopecia. A 30-month study. Arch Dermatol. 1987;123(11):1483–7.
CAS PubMed Google Scholar
Angelo T, Barbalho GN, Gelfuso GM, Gratieri T. Minoxidil topical treatment may be more efficient if applied on damp scalp in comparison with dry scalp. Dermatol Ther. 2016;29(5):330–3.
CAS PubMed Google Scholar
Kim JC, Kim MD. After-rinsing hair growth promotion of minoxidil-containing amino alpha-cyclodextrins. J Microbiol Biotechnol. 2007;17(12):1965–9.
CAS PubMed Google Scholar
Knorr F, Lademann J, Patzelt A, Sterry W, Blume-Peytavi U, Vogt A. Follicular transport route-research progress and future perspectives. Eur J Pharm Biopharm. 2009;71(2):173–80.
CAS PubMed Google Scholar
Grice JE, Ciotti S, Weiner N, Lockwood P, Cross SE, Roberts MS. Relative uptake of minoxidil into appendages and stratum corneum and permeation through human skin in vitro. J Pharm Sci. 2010;99(2):712–8.
CAS PubMed Google Scholar
Toll R, Jacobi U, Richter H, Lademann J, Schaefer H, Blume-Peytavi U. Penetration profile of microspheres in follicular targeting of terminal hair follicles. J Invest Dermatol. 2004;123(1):168–76.
CAS PubMed Google Scholar
Lademann J, Richter H, Teichmann A, Otberg N, Blume-Peytavi U, Luengo J, Weiss B, Schaefer UF, Lehr CM, Wepf R, Sterry W. Nanoparticles—an efficient carrier for drug delivery into the hair follicles. Eur J Pharm Biopharm. 2007;66(2):159–64.
CAS PubMed Google Scholar
Lademann J, Richter H, Schaefer UF, Blume-Peytavi U, Teichmann A, Otberg N, Sterry W. Hair follicles -a long-term reservoir for drug delivery. Skin Pharmacol Physiol. 2006;19(4):232–6.
CAS PubMed Google Scholar
Ghonemy S, Bessar H, Alarawi A. Efficacy and safety of a new 10% topical minoxidil versus 5% topical minoxidil and placebo in the treatment of male androgenetic alopecia: a trichoscopic evaluation. J Dermatolog Treat. 2019;32(2):236–41.
PubMed Google Scholar
Feldmann RJ, Maibach HI. Regional variation in percutaneous penetration of 14C cortisol in man. J Invest Dermatol. 1967;48(2):181–3.
CAS PubMed Google Scholar
Blume-Peytavi U, Massoudy L, Patzelt A, Lademann J, Dietz E, Rasulev U, Garcia BN. Follicular and percutaneous penetration pathways of topically applied minoxidil foam. Eur J Pharm Biopharm. 2010;76(3):450–3.
CAS PubMed Google Scholar
Canadian Pharmacists Association Monography, Minoxidil and Finasteride. In: Compendium of pharmaceuticals and specialties (CPS) 34th ed. Ottawa, Canada; 1999.
Google Scholar
Franz TJ. Percutaneous absorption of minoxidil in man. Arch Dermatol. 1985;121(2):203–6.
CAS PubMed Google Scholar
Spindler JR, Corak DL, Rohrstaff DM, et al. Topical minoxidil: long-term safety information from studies in males and females with androgenetic alopecia. Upjohn Study Report 9157–93-002. Peapack, NJ: Pharmacia and Upjohn Consumer Healthcare, March 22, 1993.
Google Scholar
Trüeb RM, Lee WS. Patient expectation management. In: Male alopecia. Cham: Springer; 2014. p. 227.
Google Scholar
Friedman HL, Seckman CE, Royer GL. Topical Minoxidil in treated hypertensive patients with male pattern baldness (protocol M7410/0058). Upjohn Study Report 7214–88-030, unpublished: 16 December 1988.
Google Scholar
Royer GL, Seckman CE, Neill JW. Topical Minoxidil safety and tolerance study in normal volunteers. Upjohn Study Report 9121-85-021, Unpublished; 23 October, 1985.
Google Scholar
Royer GL, Seckman CE, Neill JW. Twenty-eight day tolerance study of minoxidil in normals. Upjohn Study Report 9121-85-002, Unpublished; 11 March, 1985.
Google Scholar
Leenen FH, Smith DL, Unger WP. Topical minoxidil: cardiac effects in bald man. Br J Clin Pharmacol. 1988;26(4):481–5.
CAS PubMed PubMed Central Google Scholar
Shapiro J. Safety of topical minoxidil solution: a one-year, prospective, observational study. J Cutan Med Surg. 2003;7(4):322–9.
PubMed Google Scholar
Spindler JR. The safety of topical Minoxidil solution in the treatment of pattern baldness: the results of a 27-center trial. Clin Dermatol. 1988;6(4):200–12.
CAS PubMed Google Scholar
Kreindler TG. Topical Minoxidil in early androgenetic alopecia. J Am Acad Dermatol. 1987;16(3 Pt 2):718–24.
CAS PubMed Google Scholar
Trattner A, David M. Pigmented contact dermatitis from topical minoxidil 5%. Contact Dermatitis. 2002;46(4):246.
CAS PubMed Google Scholar
Aprahamian A, Escoda S, Patteau G, Merckx A, Chéron G. Minoxidil intoxication, the pharmacological agent of a hair lotion. Arch Pediatr. 2011;18(12):1297–9.
Google Scholar
Fleishaker JC, Andreadis NA, Welshman IR, Wright CE 3rd. The pharmacokinetics of 2.5- to 10-mg oral doses of minoxidil in healthy volunteers. J Clin Pharmacol. 1989;29(2):162–7.
CAS PubMed Google Scholar
Friedman ES, Friedman PM, Cohen DE, Washenik K. Allergic contact dermatitis to topical Minoxidil solution: etiology and treatment. J Am Acad Dermatol. 2002;46(2):309–12.
PubMed Google Scholar
Whitmore SE. The importance of proper vehicle selection in the detection of Minoxidil sensitivity. Arch Dermatol. 1992;128(5):653–6.
CAS PubMed Google Scholar
Fisher AA. Use of glycerin in topical minoxidil solutions for patients allergic to propylene glycol. Cutis. 1990;45(2):81–2.
CAS PubMed Google Scholar
Suzuki K, Suzuki M, Akamatsu H, Matsungaga K. Allergic contact dermatitis from Minoxidil: study of the cross-reaction to Minoxidil. Am J Contact Dermat. 2002;13(1):45–6.
CAS PubMed Google Scholar
Therianou A, Vincenzi C, Tosti A. How safe is prescribing oral minoxidil in patients allergic to topical minoxidil? J Am Acad Dermatol. 2020;S0190-9622(20):30567–3.
Google Scholar
Barbareschi M, Vescovi V, Starace M, Piraccini BM, Milani M. Propylene glycol free 5% minoxidil lotion formulation: cosmetic acceptability, local tolerability, clinical efficacy and in-vitro skin absorption evaluations. G Ital Dermatol Venereol. 2020;155(3):341–5.
PubMed Google Scholar
Goldsmith LA. Propylene glycol. Int J Dermatol. 1978;17(9):703–5.
CAS PubMed Google Scholar
LaKind JS, McKenna EA, Hubner RP, Tardiff RG. A review of the comparative mammalian toxicity of ethylene glycol and propylene glycol. Crit Rev Toxicol. 1999 Jul;29(4):331–65.
CAS PubMed Google Scholar
Glover ML, Reed MD. Propylene glycol: the safe diluent that continues to cause harm. Pharmacotherapy. 1996;16(4):690–3.
CAS PubMed Google Scholar
Ponec M, Haverkort M, Soei YL, Kempenaar J, Bodde H. Use of human keratinocyte and fibroblast cultures for toxicity studies of topically applied compounds. J Pharm Sci. 1990;79(4):312–6.
CAS PubMed Google Scholar
Neuman MG, Haber JA, Malkiewicz IM, Cameron RG, Katz GG, Shear NH. Ethanol signals for apoptosis in cultured skin cells. Alcohol. 2002;26(3):179–90.
CAS PubMed Google Scholar
Peluso AM, Misciali C, Vincenzi C, Tosti A. Diffuse hypertrichosis during treatment with 5% topical minoxidil. Br J Dermatol. 1997;136(1):118–20.
CAS PubMed Google Scholar
Blume-Peytavi U, Hillmann K, Dietz E, Canfield D, Garcia BN. A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. J Am Acad Dermatol. 2011;65(6):1126–13.
CAS PubMed Google Scholar
Dawber RP, Rundegren J. Hypertrichosis in females applying Minoxidil topical solution and in normal controls. J Eur Acad Dermatol Venereol. 2003;17(3):271–5.
CAS PubMed Google Scholar
Vexiau P, Chaspoux C, Boudou P, Fiet J, Jouanique C, Hardy N, Reygagne P. Effects of minoxidil 2% vs. cyproterone acetate treatment on female androgenetic alopecia: a controlled, 12-month randomized trial. Br J Dermatol. 2002 Jun;146(6):992–9.
CAS PubMed Google Scholar
Carson RG, Feenstra ES. Toxicologic studies with the hypotensive agent minoxidil. Toxicol Appl Pharmacol. 1977;39(1):1–11.
CAS PubMed Google Scholar
Rojansky N, Fasouliotis SJ, Ariel I, Nadjari M. Extreme caudal agenesis. Possible drug-related etiology? J Reprod Med. 2002;47(3):241–5.
PubMed Google Scholar
Rosa FW, Idanpaan-Heikkila J, Asanti R. Fetal minoxidil exposure. Pediatrics. 1987;80(1):120.
CAS PubMed Google Scholar
Smorlesi C, Caldarella A, Caramelli L, Di Lollo S, Moroni F. Topically applied minoxidil may cause fetal malformation: a case report. Birth Defects Res Part A Clin Mol Teratol. 2003;67(12):997–1001.
CAS Google Scholar
Rica Echevarría I, García Del Monte J, Delgado Rubio A, Arcangeli F, Lotti T. Severe hypertrichosis in infants due to transdermic exposure to 5% and 7% topical minoxidil. Dermatol Ther. 2020;33(6):e14230.
PubMed Google Scholar
Campese VM. Minoxidil: a review of its pharmacological properties and therapeutic use. Drugs. 1981;22(4):257–78.
CAS PubMed Google Scholar
Wu M, Yu Q, Li Q. Differences in reproductive toxicology between alopecia drugs: an analysis on adverse events among female and male cases. Oncotarget. 2016;7(50):82074–84.
PubMed PubMed Central Google Scholar
Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487–97.
CAS PubMed Google Scholar
Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23(8):1296–310.
CAS PubMed Google Scholar
Mapar MA, Omidian M. Is topical minoxidil solution effective on androgenetic alopecia in routine daily practice? J Dermatol Treat. 2007;18(5):268–70.
CAS Google Scholar
Gogtay JA, Panda M. Minoxidil topical foam: a new kid on the block. Int J Trichol. 2009;1(2):142.
Google Scholar
Rogaine In-Home Use Test, Final Report. December 2003. Data on File, Pfizer, Inc.
Google Scholar
Stehle R, Ewing G, Rundegren J, Kohut B. Update of minoxidil from a new foam formulation devoid of propylene glycol to hamster ear hair follicles. J Invest Dermatol. 2005;125 (Supplement 1s) Supp:A101.
Google Scholar
Rundegren J, Westin A, Kohut B. Hair growth efficacy assessment of a new topical minoxidil foam formulation in the stumptail macaque. J Invest Dermatol. 2005;125 (Supplement 1s) Supp:A98.
Google Scholar
Hasanzadeh H, Nasrollahi SA, Halavati N, Saberi M, Firooz A. Efficacy and safety of 5% minoxidil topical foam in male pattern hair loss treatment and patient satisfaction. Acta Dermatovenerol Alp Pannonica Adriat. 2016;25(3):41–4.
PubMed Google Scholar
Hillmann K, Garcia Bartels N, Kottner J, Stroux A, Canfield D, Blume-Peytavi U. A single-centre, randomized, double-blind, placebo-controlled clinical trial to investigate the efficacy and safety of minoxidil topical foam in frontotemporal and vertex androgenetic alopecia in men. Skin Pharmacol Physiol. 2015;28(5):236–44.
CAS PubMed Google Scholar
Blume-Peytavi U, Shapiro J, Messenger AG, Hordinsky MK, Zhang P, Quiza C, Doshi U, Olsen EA. Efficacy and safety of once-daily minoxidil foam 5% versus twice-daily minoxidil solution 2% in female pattern hair loss: a phase III, randomized, investigator-blinded study. J Drugs Dermatol. 2016;15(7):883–9.
CAS PubMed Google Scholar
Bergfeld W, Washenik K, Callender V, Zhang P, Quiza C, Doshi U, Blume-Peytavi U. A phase III, multicenter, parallel-design clinical trial to compare the efficacy and safety of 5% minoxidil foam versus vehicle in women with female pattern hair loss. J Drugs Dermatol. 2016;15(7):874–81.
CAS PubMed Google Scholar
Jun-Bo T, Zhuang-Qun Y, Xi-Jing H, Ying X, Yong S, Zhe X, Tao C. Effect of ethosomal minoxidil on dermal delivery and hair cycle of C57BL/6 mice. J Dermatol Sci. 2007;45(2):135–7.
PubMed Google Scholar
Mura S, Pirot F, Manconi M, Falson F, Fadda AM. Liposomes and niosomes as potential carriers for dermal delivery of minoxidil. J Drug Target. 2007;15(2):101–8.
CAS PubMed Google Scholar
Kwon TK, Kim JC. In vitro skin permeation of monoolein nanoparticles containing hydroxypropyl beta-cyclodextrin/minoxidil complex. Int J Pharm. 2010;392(1–2):268–73.
CAS PubMed Google Scholar
Silva AC, Santos D, Ferreira DC, Souto EB. Minoxidil-loaded nanostructured lipid carriers (NLC): characterization and rheological behaviour of topical formulations. Pharmazie. 2009;64(3):177–82.
CAS PubMed Google Scholar
Zhao Y, Brown MB, Jones SA. The effects of particle properties on nanoparticle drug retention and release in dynamic minoxidil foams. Int J Pharm. 2010;383(1–2):277–84.
CAS PubMed Google Scholar
Mura S, Manconi M, Sinico C, Valenti D, Fadda AM. Penetration enhancer-containing vesicles (PEVs) as carriers for cutaneous delivery of minoxidil. Int J Pharm. 2009;380(1–2):72–9.
CAS PubMed Google Scholar
Pereira MN, Schulte HL, Duarte N, Lima EM, Sá-Barreto LL, Gratieri T, Gelfuso GM, Cunha-Filho MS. Solid effervescent formulations as new approach for topical minoxidil delivery. Eur J Pharm Sci. 2017;96:411–9.
CAS PubMed Google Scholar
Wang W, Chen L, Huang X, Shao A. Preparation and characterization of minoxidil loaded nanostructured lipid carriers. AAPS PharmSciTech. 2017;18(2):509–16.
CAS PubMed Google Scholar
Lopedota A, Denora N, Laquintana V, et al. Alginate-based hydrogel containing minoxidil/hydroxypropyl-β-cyclodextrin inclusion complex for topical alopecia treatment. J Pharm Sci. 2018;107(4):1046–54.
CAS PubMed Google Scholar
Kumar P, Singh SK, Handa V, Kathuria H. Oleic acid nanovesicles of minoxidil for enhanced follicular delivery. Medicines (Basel). 2018;5(3):103.
CAS PubMed PubMed Central Google Scholar
Jain B, Singh B, Katare OP, Vyas SP. Development and characterization of minoxidil-loaded liposomal system for delivery to pilosebaceous units. J Liposome Res. 2010;20(2):105–14.
CAS PubMed Google Scholar
Yang X, Thai KE. Treatment of permanent chemotherapy-induced alopecia with low dose oral minoxidil. Australas J Dermatol. 2016;57(4):e130–2.
PubMed Google Scholar
Fiedler-Weiss VC, Rumsfield J, Buys CM, West DP, Wendrow A. Evaluation of oral minoxidil in the treatment of alopecia areata. Arch Dermatol. 1987;123(11):1488–90.
CAS PubMed Google Scholar
Perera E, Sinclair R. Treatment of chronic telogen effluvium with oral minoxidil: a retrospective study. F1000Res. 2017;6:1650.
PubMed PubMed Central Google Scholar
Lueangarun S, Panchaprateep R, Tempark T, et al. Efficacy and safety of oral minoxidil 5 mg daily during 24-week treatment in male androgenetic alopecia. J Am Acad Dermatol. 2015;72(5):AB113.
Google Scholar
Sinclair R. Treatment of female pattern hair loss with oral minoxidil. Austral J Dermatol. 2016;57(Suppl 1):27.
Google Scholar
Sinclair RD. Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone. Int J Dermatol. 2018;57(1):104–9.
CAS PubMed Google Scholar
Beach RA. Case series of oral minoxidil for androgenetic and traction alopecia: tolerability & the five C’s of oral therapy. Dermatol Ther. 2018;31(6):e12707.
PubMed PubMed Central Google Scholar
Jimenez-Cauhe J, Saceda-Corralo D, Rodrigues-Barata R, Hermosa-Gelbard A, Moreno-Arrones OM, Fernandez-Nieto D, Vaño-Galvan S. Effectiveness and safety of low-dose oral minoxidil in male androgenetic alopecia. J Am Acad Dermatol. 2019. pii: S0190–9622(19)30685–1
Google Scholar
Pirmez R, Salas-Callo CI. Very low dose oral minoxidil in male androgenetic alopecia: a study with quantitative trichoscopic documentation. J Am Acad Dermatol. 2019. pii: S0190–9622(19)32737–9
Google Scholar
Ramos PM, Sinclair RD, Kasprzak M, Miot HA. Minoxidil 1 mg orally versus minoxidil 5% solution topically for the treatment of female pattern hair loss: a randomized clinical trial. J Am Acad Dermatol. 2019. pii: S0190–9622(19)32666–0
Google Scholar
Sinclair R, Trindade de Carvalho L, Ferial Ismail F, Meah N. Treatment of male and female pattern hair loss with sublingual minoxidil: a retrospective case-series of 64 patients. J Eur Acad Dermatol Venereol. 2020;34(12):e795–6.
CAS PubMed Google Scholar
Beach RA, McDonald KA, Barrett BM. Tolerated, effective, successful: low dose oral minoxidil for treating alopecia, a 3-year North American retrospective case series. J Am Acad Dermatol. 2020;S0190-9622(20):32844–9.
Google Scholar
Ortega-Quijano D, Jimenez-Cauhe J, Fernandez-Nieto D, Saceda-Corralo D, Vaño-Galvan S. Comment on “Low dose oral minoxidil for treating alopecia: A 3-year North American retrospective case series”: adding further evidence about side effects. J Am Acad Dermatol. 2021;S0190-9622(20):33234–5.
Google Scholar
Panchaprateep R, Lueangarun S. Efficacy and safety of oral minoxidil 5 mg once daily in the treatment of male patients with androgenetic alopecia: an open-label and global photographic assessment. Dermatol Ther (Heidelb). 2020;10(6):1345–57.
PubMed Google Scholar
Jha AK, Sonthalia S, Zeeshan MD, Vinay K. Efficacy and safety of very-low-dose oral minoxidil 1.25 mg in male androgenetic alopecia. J Am Acad Dermatol. 2020;83(5):1491–3.
CAS PubMed Google Scholar
Rodrigues-Barata R, Moreno-Arrones OM, Saceda-Corralo D, et al. Low-dose oral minoxidil for female pattern hair loss: a unicenter descriptive study of 148 women. Skin Appendage Disord. 2020;6(3):175–6.
PubMed PubMed Central Google Scholar
Vastarella M, Cantelli M, Patrì A, Annunziata MC, Nappa P, Fabbrocini G. Efficacy and safety of oral minoxidil in female androgenetic alopecia. Dermatol Ther. 2020;33(6):e14234.
CAS PubMed Google Scholar
Randolph M, Tosti A. Oral minoxidil treatment for hair loss: a review of efficacy and safety. J Am Acad Dermatol. 2020;S0190-9622(20):32109–5.
Google Scholar
Jimenez-Cauhe J, Saceda-Corralo D, Rodrigues-Barata R, et al. Safety of low-dose oral minoxidil treatment for hair loss. A systematic review and pooled-analysis of individual patient data. Dermatol Ther. 2020;33(6):e14106.
CAS PubMed Google Scholar
Jimenez-Cauhe J, Saceda-Corralo D, Rodrigues-Barata R, et al. Characterization and management of hypertrichosis induced by low-dose oral minoxidil in the treatment of hair loss. J Am Acad Dermatol. 2020;S0190-9622(20):32594–9.
Google Scholar
do Nascimento IJB, Harries M, Rocha VB, Thompson JY, Wong CH, Varkaneh HK, Guimarães NS, Rocha Arantes AJ, Marcolino MS. Effect of oral minoxidil for alopecia: systematic review. Int J Trichol. 2020;12(4):147–55.
Google Scholar
Benmously Mlika R, Ben Hamida M, Hammami H, Dorbani Ben Thabet I, Rouatbi M, Mokhtar I. Long-pulsed Nd:YAG laser in the treatment of facial hypertrichosis during topical minoxidil therapy. J Cosmet Laser Ther. 2013;15(4):217–8.
PubMed Google Scholar
Keusch GW, Weidmann P, Campese V, Lee DB, Upham AT, Massry SG. Minoxidil therapy in refractory hypertension analysis of 155 patients. Nephron. 1978;21(1):1–15.
CAS PubMed Google Scholar
Hagstam KE, Lundgren R, Wieslander J. Clinical experience of long-term treatment with minoxidil in severe arterial hypertension. Scand J Urol Nephrol. 1982;16(1):57–63.
CAS PubMed Google Scholar
Pfizer Canada I. LONITEN (minoxidil tablets USP) Product Monograph. Quebec: Kirland; 2013.
Google Scholar
Sanabria B, de Nardo VT, Miot HA, Ramos PM. Adverse effects of low-dose oral minoxidil for androgenetic alopecia in 435 patients. J Am Acad Dermatol. 2020;S0190-9622(20):33074–7.
Google Scholar
Jimenez-Cauhe J, et al. Reply to “Very low dose oral minoxidil in male androgenetic alopecia: a study with quantitative trichoscopic documentation”. J Am Acad Dermatol. 2019. pii: S0190–9622(19)32738–0
Google Scholar
Zoellner Y, Balp MM, Marco AG. The role of galenic innovation in improving treatment compliance and persistence: three case studies. Clinicoecon Outcomes Res. 2011;3:109–16.
PubMed PubMed Central Google Scholar
Gajjar PC, Mehta HH, Barvaliya M, Sonagra B. Comparative study between mesotherapy and topical 5% minoxidil by dermoscopic evaluation for androgenic alopecia in male: a randomized controlled trial. Int J Trichol. 2019;11(2):58–67.
Google Scholar
Uzel BPC, Takano GHS, Chartuni JCN, Cesetti MV, Gavioli CFB, Lemes AM, Costa IMC. Intradermal injections with 0.5% minoxidil for the treatment of female androgenetic alopecia: a randomized, placebo-controlled trial. Dermatol Ther. 2020;34(1):e14622.
PubMed Google Scholar

Download references

Author information

Authors and Affiliations

Athens, Attiki, Greece
Konstantinos Anastassakis

Authors

Konstantinos Anastassakis
View author publications
You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

About this chapter

Cite this chapter

Anastassakis, K. (2022). Minoxidil. In: Androgenetic Alopecia From A to Z . Springer, Cham. https://doi.org/10.1007/978-3-031-08057-9_1

Download citation

DOI: https://doi.org/10.1007/978-3-031-08057-9_1
Published: 27 October 2022
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-08056-2
Online ISBN: 978-3-031-08057-9
eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics